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E-mail address: dmasys@u.washington.edu (D.R. MThe era of ‘‘Personalized Medicine,’’ guided by individual molecular variation in DNA, RNA, expressed
proteins and other forms of high volume molecular data brings new requirements and challenges to
the design and implementation of Electronic Health Records (EHRs). In this article we describe the char-
acteristics of biomolecular data that differentiate it from other classes of data commonly found in EHRs,
enumerate a set of technical desiderata for its management in healthcare settings, and offer a candidate
technical approach to its compact and efﬁcient representation in operational systems.
 2011 Elsevier Inc. All rights reserved.1. Introduction
High throughput technologies for analyzing DNA, DNA methyl-
ation, RNA, proteins and other biologically important molecules
are an essential infrastructure for the nascent era of clinical care
that is tailored to one’s unique ‘molecular self.’ The availability of
low-cost complete genome sequences portends a ﬂood of molecu-
lar sequence data being generated in clinical care contexts, and the
need to efﬁciently store, display, and use that data for healthcare
purposes including patient-speciﬁc clinical decision support [1,2].
The majority of common diseases have their roots in biomolec-
ular structures and interactions; although these molecules and
interactions that make up human physiology are highly regular,
specialized, redundant and fault-tolerant, their complexity and
variety in the body and within and between individuals is stagger-
ing. Approximately 1.5% of the 3 billion base pairs in the human
genome code for proteins [3], and each of those 45 million base
pairs can acquire polymorphisms, many of them non-fatal. Further
complicating the picture, the approximately 50 trillion cells in thell rights reserved.
Place, Sequim, WA 98382,
asys).body may undergo a total of ten quadrillion cell divisions during a
human lifespan, each carrying with it further risk of genetic dam-
age. Each of the 200 known cell types has its own gene expression
proﬁle in healthy and diseased states that may also demonstrate
secular changes.
While the basic genome of individuals is likely the ﬁrst, most
complex source of data to challenge current EHR structures, other
‘‘omics’’ data such as gene expression proﬁles are already being
used in clinical decision-making [4,5]. The structure of unitary
observations (e.g., single base pairs of DNA) is simple. However,
the volume and complexity of the data and its annotation is large
enough to have important implications for its storage and use
within EHR systems. Based on consideration of the nature of the
data, and the state of genomic science and clinical care, we sought
to describe a set of desirable functional characteristics for any EHR
that will incorporate individual molecular variation into the provi-
sion of healthcare services.2. Materials and methods
The content of this manuscript was assembled for presentation
and reﬁned by interdisciplinary group discussion at an invited
workshop on ‘‘Integration of Genetic Test Results into Electronic
420 D.R. Masys et al. / Journal of Biomedical Informatics 45 (2012) 419–422Medical Records’’ convened by the National Heart Lung and Blood
Institute, and held in Bethesda, MD on August 2–3, 2011.
3. Results
Table 1 presents a set of seven desiderata for the integration of
genomic and other high volume biomolecular data into EHRs. We
offer these functional characteristics both as a conceptual guide-
line for the design or extension of EHRs, and for their potential util-
ity as evaluation criteria for the ‘meaningful use’ of EHRs to
manage these types of data. The explanation and reasoning behind
these desiderata are provided here.
3.1. Maintain separation of primary molecular observations from the
clinical interpretations of those data
A common current practice for the reporting of genetic varia-
tion by clinical laboratories is to acquire a large number of molec-
ular observations via high throughput technologies, such as solid
state chips that measure hundreds to thousands of molecular vari-
ants. Laboratories then deliver into the health record a report in
document format on paper, through an electronic interface be-
tween the laboratory and EHR or as open standard for document
exchange such as PDF, that cites only a small number of the obser-
vations made combined with professional interpretation of the
signiﬁcance of those observations. This parallels the current
reporting practice in diagnostic medicine, pathology and radiology.
This practice is potentially limiting in the emerging era of person-
alized medicine in three respects. First, it embodies a lossy sam-
pling approach where only a subset of data is reported via a ﬁlter
of professional opinion (albeit guided by then-current scientiﬁc
evidence), and the remainder of the primary observation data is
either discarded or held inaccessible. Second, it renders the pri-
mary data in a document format that is optimized only for human
interpretation and ill-suited to the use of computer-based decision
support rules. Third, it represents a point-in-time interpretation in
an immature ﬁeld of clinical science that is rapidly changing. The
vast majority of molecular variants are currently of unknown sig-
niﬁcance, but it can be reasonably expected that determinations
of signiﬁcance or lack thereof will be assigned to increasing num-
bers of variants as genomic science evolves. Thus, the separation of
primary observations from their interpretations, and the ability to
update and improve those interpretations at a later date, will more
signiﬁcantly impact biomolecular data than other common clinical
data types. Novel approaches to dynamic reporting of clinical
laboratory genotyping and associated genomic knowledge bases
are currently being developed [6,7].
3.2. Support lossless data compression from primary molecular
observations to clinically manageable subsets
The large volume of each individual’s DNA, protein and related
data – hundreds of gigabytes to terabytes in its raw form – exceeds
the capacity of commonly available network bandwidth and disk
storage in healthcare settings. In the absence of a major advanceTable 1
Desiderata for the integration of genomic and other high volume biomolecular data into E
1 Maintain separation of primary molecular observations from th
2 Support lossless data compression from primary molecular obse
3 Maintain linkage of molecular observations to the laboratory m
4 Support compact representation of clinically actionable subsets
5 Simultaneously support human-viewable formats and machine-
6 Anticipate fundamental changes in the understanding of human
7 Support both individual clinical care and discovery sciencein data storage and transmission capabilities, this large volume of
data will need to be compressed. Other high volume digital data-
sets do exist in healthcare, notably digital radiography and com-
puted tomography, and specialized digital infrastructures (such
as Picture Archiving and Communications Systems – PACS [8])
have been developed to store and display these data. A variety of
data compression algorithms and image representation formats
have been developed to accommodate the efﬁcient transfer and
viewing of clinical digital images. Most of these formats offer
‘lossy’ compression (reduction in ﬁle size associated with removal
of data such that the ability to faithfully reconstruct all of the con-
tent of the original large volume source image is sacriﬁced). Since
the key features of clinical images are often not exquisitely depen-
dent upon single pixel level detail, this is a robust and useful
approach to data compression for many types of health-related
images. In contrast, changing even a single letter of the ‘genetic
alphabet’ (i.e. a point mutation) may dramatically affect human
physiology. In some cases the signiﬁcance of such changes is well
known, as demonstrated by sickle cell disease and other inherited
disorders [9]. Therefore, any sufﬁcient data compression approach
needs to be able to produce a fully accurate copy of the original
sequence.
3.3. Maintain linkage of molecular observations to the laboratory
methods used to generate them
Measurement technologies for DNA sequence and expressed
proteins are rapidly evolving, and all are constrained by non-zero
error rates and ‘‘blind spots’’ representing biological phenomena
that are not detectable by the method. For the foreseeable future,
the laboratory instruments, chemistry and methods used to obtain
high throughput molecular measurements such as single nucleo-
tide polymorphism (SNP) arrays, exome sequences and full genome
sequences will continue to evolve, with successive generations of
instruments having different strengths and weaknesses. Genomic
sequence data representation standards such as the Genome Varia-
tion Format (GVF) [10] and the Human Genome Variation Society’s
nomenclature for the description of sequence variants [11] are
being proposed to provide common coordination across sequencing
platforms. For this reason it will be essential that EHRs maintain
provenance that links molecular observations with the laboratory
methods used to generate those observations. This binding ofmeth-
ods with results is a structural component of widely used labora-
tory data standards such as LOINC [12], and is a feature of
proposed and evolving data standards such as HL7 [13].3.4. Support compact representation of clinically actionable subsets for
optimal performance
An important functionality of EHRs is the ability to rapidly ﬁnd,
assemble, and display the relevant clinical data for individual
patients and groups of patients. Since the amount of molecular se-
quence data that currently has demonstrated clinical signiﬁcance
is a tiny fraction of the full genome and proteome, and it is neither
computationally feasible nor desirable to query or analyze one’sHRs.
e clinical interpretations of those data
rvations to clinically manageable subsets
ethods used to generate them
for optimal performance
readable formats in order to facilitate implementation of decision support rules
molecular variation
Fig. 1. Layered classes and data sizes of EHR-relevant genomic data.
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such as drug prescribing or diagnostic test ordering. EHR systems
need to access and display relevant information, and/or recognize
and act upon clinically relevant molecular patterns with sub-
second response times [14]. These requirements for speed and
efﬁciency make the creation of compact, derived forms of data
representing the underlying molecular variation an attractive tech-
nical option in EHR systems. These derived observations can be
efﬁciently represented as short ‘‘keywords’’ or codes representing
a physiologic state. For example, the observation that an individual
has a minor allele variant such as CYP2C192, that is associated
with altered metabolism of commonly prescribed drugs, can be
represented by a compact code of just a few unique alphanumeric
characters or a global unique identiﬁer from structured vocabu-
lary/ontology such as the Clinical Bioinformatics Ontology (CBO)
[15].
3.5. Simultaneously support human-viewable formats and machine-
readable formats in order to facilitate implementation of decision
support rules
In its simplest form, a single observation such as the value of a
single nucleotide polymorphism, is recognizable upon inspection
by a healthcare professional, and as noted above, genotyping re-
sults are commonly displayed as laboratory report documents.
However, molecular variation data introduces into clinical practice
volumes of data whose complexity routinely exceeds the bounds of
unaided human cognition [16]. The rapidly expanding literature on
the association between molecular variation patterns and clinical
phenomena [17] makes it difﬁcult for even genetic medicine spe-
cialists to stay current, and far exceeds the interpretive capacity
of most non-specialist providers. Consequently, perhaps more than
for any class of clinical data that has preceded it into the EHR,
molecular variation data will beneﬁt from the implementation of
clinical decision support rules that are designed to recognize key
patterns (such as DNA variation that predicts altered drug re-
sponse) and guide practitioners via patient-speciﬁc alerts and
reminders at clinically relevant times. The inherently cryptic nat-
ure of genetic polymorphisms lobbies for systems approaches that
guide not only specialists, but also providers who ‘‘do not know
what they do not know’’ with respect to clinically important
molecular variation [18].
3.6. Anticipate fundamental changes in the understanding of human
molecular variation
Designing EHR capacity based on the expectation that an indi-
vidual has a single, unique genome will be insufﬁcient to accom-
modate the actual data requirements for EHRs. This premise,
commonly associated with the genome contained in germline
(i.e. heritable) DNA, needs to at a minimum be modiﬁed to accom-
modate diseases such as cancer, in which somatic mutations occur
[1,19]. Thus, EHR systems need to anticipate circumstances such as
a ‘‘unique genome for each metastasis’’. The state of the germline
DNA is generally inferred through sampling of leukocyte DNA,
generally from blood, and less often from saliva. Emerging evi-
dence that the DNA represented in the leukocytes may undergo
structural changes as a result of normal aging [20] also suggests
that as genomic science unfolds, EHRs may need to store multiple
genome-scale datasets over an individual’s lifetime. Other cell-, tis-
sue- , organ-, and disease-speciﬁc genetic variations over time may
yet be discovered. The off-cited use case of storing 3 billion bases of
DNA (which in reality is a minimum of 6 billion, since humans are
diploid organisms) even when supplemented with data on copy
number and splicing variation is only a starting point for a much
larger universe of person-speciﬁc molecular variation data.3.7. Support both individual clinical care and discovery science
Historically, the intersection of clinical care and biomedical re-
search has been relatively minimal, as evidenced by the small frac-
tion of eligible patients who enroll in clinical trials [21,22].
Genomic science has unprecedented requirements for large num-
bers of individuals, each of whom has available large numbers of
molecular observations, in order to confront the ‘curse of dimen-
sionality’ (i.e. the expected false discovery rate of patterns that
arise by chance when thousands to millions of simultaneous obser-
vations are made). Thus, to advance clinical science as rapidly and
robustly as possible, the ability to support genomic discovery sci-
ence as a secondary use of data acquired for person-speciﬁc care
is at least a compelling opportunity, if not a social obligation to fu-
ture generations. Such uses will be modulated by issues of consent
and privacy, however a research focus on human molecular varia-
tion, and the emerging capability to measure that variation at all
locations where it occurs in the genome and proteome, makes each
individual’s genome potentially a uniquely valuable research re-
source. Well-structured genomic information within the EHR will
expedite secondary use of that data to support new discovery.4. Discussion
A technical approach to lossless data compression for biomolec-
ular sequences in EHRs.
Fig. 1 presents a size hierarchy of genomic data types that are of
relevance to EHRs and may need to be stored and analyzed for
optimal, individualized care. The current technologies such as ‘next
generation’ (nextgen) DNA sequencing, with automated repeated
observations of a single nucleotide base in order to assemble a
consensus DNA sequence, generates primary data that occupies
hundreds of gigabytes or more of disk space. Like the technology
itself, the analytical software that interprets these data to generate
a consensus sequence of a few gigabytes is evolving rapidly, so
there is a need to preserve the source ﬁles for potential future
re-analysis.
The layered approach to increasingly compact representations
of lossless data compression shown in Fig. 1 can beneﬁt from an
essential feature of human biology, which is that we are much
more alike than we are different at a molecular level. First approx-
imations of 1–4 million differences [23] contained in a roughly
3 billion nucleotide genome suggest that EHRs can achieve two or-
ders of magnitude (100 fold) data size reduction by representing
personal nucleotide and/or protein sequences as the difference
between the individual and what we propose calling a ‘‘Clinical
422 D.R. Masys et al. / Journal of Biomedical Informatics 45 (2012) 419–422Standard Reference Genome’’ (CSRG). Such a sequence would not
need to represent any biological reality and would best serve its
purpose if it generated the smallest set of differences across a large
number of complete human genomes. This would be achieved by
inclusion of the most common allele at each locus in the CSRG,
without regard to actual clinical, ethnic or racial data. While vari-
ous groups generating sequence data use already this mode for
data compression, a single standard does not currently exist. As
with the binding of molecular observations to the methods used
to generate them, revisions of the CSRG to reﬂect evolving knowl-
edge or technology are easily managed by applying and recording a
unique version identiﬁer for each iteration. Generation and wide-
spread use of a CSRG would be a boon to the ability to store and
interpret biomolecular sequence data in EHRs without data loss
relative to the source observations.Acknowledgment
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